Inventaire - your friends and communities are your best library

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

автор

Thomas Graeber

Bartosz Chmielowski

Antoni Ribas

1966 -

Begoña Comin-Anduix

Ángel García Díaz

Siwen Hu-Lieskovan

опубликовано в: New England Journal of Medicine

дата публикации: 2016-07-13

язык: английский язык

Cites articles 37

Дата

Заголовок

Авторы

2016-04-01

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

Caroline Robert, Antoni Ribas, Bartosz Chmielowski, Richard W. Joseph, Adil Daud, Anthony M Joshua, Richard F. Kefford, Jedd D Wolchok, F Stephen Hodi, Roxana S. Dronca, Tara C Gangadhar
2015-09-10

Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab

Bartosz Chmielowski, Antoni Ribas, Luis H Camacho
2015-09

Adaptive Immune Resistance: How Cancer Protects from Immune Attack

Antoni Ribas
2015-09

Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
2015-06-25

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert, Adil Daud, Christian U Blank
2015-02-09

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

Dirk Schadendorf, Caroline Robert, Tai-Tsang Chen, Jedd D Wolchok, F Stephen Hodi
2015-01-22

Nivolumab in previously untreated melanoma without BRAF mutation

Georgina V. Long, Michele Maio, Piotr Rutkowski, Ewa Kalinka-Warzocha, Julie Charles, Vanna Chiarion Sileni, Ana Arance, Paolo Antonio Ascierto
2015-08-24

Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy

Thomas F Gajewski
2014-12-06

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

Ahmad Halwani, Gordon J. Freeman, Margaret A Shipp
2014-11-01

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Christina L. Harview, Bartosz Chmielowski, Antoni Ribas
2014-10-07

Genetic evolution of T-cell resistance in the course of melanoma progression

Francesco Sabbatino, Klaus G Griewank, Antje Sucker, Dirk Schadendorf, Soldano Ferrone, Christine Falk
2014-09-12

Interferon receptor signaling in malignancy: a network of cellular pathways defining biological outcomes

Eleanor N. Fish
2014-07-15

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Richard F. Kefford, Jeffrey S Weber, Anthony M Joshua, Richard W. Joseph, Bartosz Chmielowski, Adil Daud, Jedd D Wolchok, Antoni Ribas, F Stephen Hodi, Roxana S. Dronca, Tara C Gangadhar
2014-05-08

Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma

Bjoern Titz, Thomas Graeber, Antoni Ribas
2013-11-21

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

Bartosz Chmielowski, Antoni Ribas, Georgina V. Long, Richard F. Kefford, Xiangju Kong, Jeffrey A Sosman, Hubing Shi, Aayoung Hong, Richard C Koya, Gatien Moriceau, Willy Hugo, Thinle Chodon
2013-07-11

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Bartosz Chmielowski, Antoni Ribas, Caroline Robert, Richard W. Joseph, Anthony M Joshua, Adil Daud, Richard F. Kefford, Jedd D Wolchok, F Stephen Hodi, Roxana S. Dronca, Tara C Gangadhar
2012-05

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data

Chris Sander, Bülent Arman Aksoy, Ethan Cerami, Ugur Dogrusoz, Boris Reva, Jianjiong Gao, Anders Jacobsen, Nikolaus Schultz, Selcuk Onur Sumer, Yevgeniy Antipin
2012-03-22

The blockade of immune checkpoints in cancer immunotherapy

Drew M Pardoll
2012-01-23

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma

Розенберг, Стивен
2011-04-15

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

Nicholas P. Restifo, Розенберг, Стивен, John R Wunderlich, Udai S Kammula, Marybeth S Hughes, Carolyn Laurencot, Seth M Steinberg
2011-03-01

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

Chyi-Chia R Lee
2010-12-16

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Antoni Ribas, Hubing Shi, Grant McArthur, Stanley F Nelson
2009-12-01

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Jedd D Wolchok, F Stephen Hodi, Michele Maio
2009-06-18

Circos: an information aesthetic for comparative genomics

Inanc Birol, Steven Jones, Randy D Gascoyne, Joseph M Connors, Marco Marra, Martin Krzywinski, Jacqueline E. Schein, Doug E Horsman
2009-01

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Daniel J. Sargent
2005-04-01

IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression

Lloyd J. Old
2004

The three Es of cancer immunoediting

Lloyd J. Old
2002-11

Cancer immunoediting: from immunosurveillance to tumor escape

Lloyd J. Old
2000-02-01

High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update
2000-01-01

Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance
1998-06-01

Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice

Lloyd J. Old
1997-04

The IFN gamma receptor: a paradigm for cytokine receptor signaling,THE IFNγ RECEPTOR:A Paradigm for Cytokine Receptor Signaling

Статья - wd:Q37222679

Добро пожаловать в Inventaire

the library of your friends and communities

узнать больше